\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\ \(1\)\
\-\ nonpalpable\\,\\ nontender\\ thyroid\\ gland\\.\ \(0\)\
\-\ labs\\:\ \(4\)\
\-\ tsh\\ of\\ 0\\.08\\ uiu\\/ml\\,\\ and\\ free\\ t4\\ of\\ 63\\.8\\ pmol\\/l\\.\\ \\ \ \(0\)\
\-\ the\\ 25\\-hr\\ raiu\\ \\=\\ \\ 0\\.9\\ \\%\\ \\(normal\\ 8\\ \\-\\ 30\\%\\)\\.\ \(0\)\
\-\ amiodarone\\ was\\ discontinued\\ and\\ methimazole\\ was\\ initiated\\.\ \(0\)\
\-\ absent\\ uptake\\ within\\ the\\ thyroid\\ and\\ decreased\\ 24\\-hour\\ radioactive\\ iodine\\ uptake\\.\\ \\ findings\\ consistent\\ with\\ amiodarone\\ induced\\ hyperthyroidism\\.\ \(0\)\
\-\ amiodarone\\ induced\\ thyroiditis\ \(0\)\
\-\ subacute\\ thyroiditis\ \(5\)\
\-\ factitious\\ hyperthyroidism\\ \\(thyroid\\ hormone\\ supplementation\\)\ \(0\)\
\-\ struma\\ ovari\\ \\(ovarian\\ carcinoma\\)\ \(0\)\
\-\ jod\\ basedow\\ phenomenon\ \(0\)\
\-\ 90\\ year\\ old\\ female\\ with\\ history\\ of\\ tremors\\,\\ lower\\ extremity\\ edema\\ and\\ insomnia\\.\\ \\ she\\ has\\ a\\ history\\ of\\ hyperthyroidism\\ and\\ amiodarone\\ use\\.\ \(0\)\
\-\ two\\ types\\ of\\ hyperthyroidism\\ related\\ to\\ amiodarone\\ may\\ occur\\.\\ \\ type\\ i\\ \\(iodine\\-induced\\ hyperthyroidism\\)\\ and\\ type\\ ii\\ \\(destructive\\ thyrotoxicosis\\)\\.\\ \\ type\\ i\\ often\\ has\\ low\\ raiu\\ \\(but\\ the\\ raiu\\ may\\ be\\ normal\\ or\\ rarely\\ elevated\\)\\;\\ and\\ this\\ type\\ often\\ responds\\ to\\ antithyroid\\ medications\\.\\ \\ type\\ ii\\ always\\ presents\\ with\\ low\\ raiu\\ and\\ is\\ typically\\ responsive\\ to\\ glucocorticoids\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ amiodarone\\:\\ 0\\.4453037997199128\ \(0\)\
\-\ hyperthyroidism\\:\\ 0\\.38507354886853956\ \(0\)\
\-\ raiu\\:\\ 0\\.3275315502210869\ \(0\)\
\-\ type\\:\\ 0\\.22972485019747207\ \(0\)\
\-\ induced\\:\\ 0\\.2037528880430078\ \(0\)\
\-\ thyroid\\:\\ 0\\.1614722517473343\ \(0\)\
\-\ thyroiditis\\:\\ 0\\.15174075455305835\ \(0\)\
\-\ iodine\\:\\ 0\\.151023901097543\ \(0\)\
\-\ and\\:\\ 0\\.11321913377861591\ \(0\)\
\-\ nonpalpable\\:\\ 0\\.10952865377711722\ \(0\)\
\-\ antithyroid\\:\\ 0\\.10952865377711722\ \(0\)\
\-\ ii\\:\\ 0\\.10799872599085703\ \(0\)\
\-\ uptake\\:\\ 0\\.10532788623297842\ \(0\)\
\-\ ovari\\:\\ 0\\.10466047599555342\ \(0\)\
\-\ methimazole\\:\\ 0\\.0985272973270509\ \(0\)\
\-\ basedow\\:\\ 0\\.0985272973270509\ \(0\)\
\-\ tremors\\:\\ 0\\.09147009332810004\ \(0\)\
\-\ responds\\:\\ 0\\.09020509244116132\ \(0\)\
\-\ often\\:\\ 0\\.08937799983844598\ \(0\)\
\-\ insomnia\\:\\ 0\\.08906075994398256\ \(0\)\
\-\ supplementation\\:\\ 0\\.08801606622377424\ \(0\)\
\-\ thyrotoxicosis\\:\\ 0\\.0853369146595975\ \(0\)\
\-\ discontinued\\:\\ 0\\.08456203911944846\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.08456203911944846\ \(0\)\
\-\ radioactive\\:\\ 0\\.08249873555572178\ \(0\)\
\-\ phenomenon\\:\\ 0\\.07873283627486352\ \(0\)\
\-\ low\\:\\ 0\\.07859859798117029\ \(0\)\
\-\ responsive\\:\\ 0\\.07784306604245365\ \(0\)\
\-\ initiated\\:\\ 0\\.07482568355632085\ \(0\)\
\-\ destructive\\:\\ 0\\.07297488826088984\ \(0\)\
\-\ hormone\\:\\ 0\\.06973719860802664\ \(0\)\
\-\ may\\:\\ 0\\.06893154349770562\ \(0\)\
\-\ t4\\:\\ 0\\.06869250488781832\ \(0\)\
\-\ of\\:\\ 0\\.067014868390939\ \(0\)\
\-\ tsh\\:\\ 0\\.066174515524866\ \(0\)\
\-\ always\\:\\ 0\\.06465268337500026\ \(0\)\
\-\ nontender\\:\\ 0\\.06451059409870517\ \(0\)\
\-\ types\\:\\ 0\\.06369165831197912\ \(0\)\
\-\ has\\:\\ 0\\.06256746361457796\ \(0\)\
\-\ rarely\\:\\ 0\\.06109193197935374\ \(0\)\
\-\ ovarian\\:\\ 0\\.05834919825218992\ \(0\)\
\-\ medications\\:\\ 0\\.0574533900997543\ \(0\)\
\-\ absent\\:\\ 0\\.05618838921281558\ \(0\)\
\-\ normal\\:\\ 0\\.05592711348777132\ \(0\)\
\-\ gland\\:\\ 0\\.055636273378210095\ \(0\)\
\-\ 90\\:\\ 0\\.05472724668021587\ \(0\)\
\-\ free\\:\\ 0\\.05331309600297787\ \(0\)\
\-\ use\\:\\ 0\\.052403490306419734\ \(0\)\
\-\ history\\:\\ 0\\.052333445808625666\ \(0\)\
\-\ related\\:\\ 0\\.052048095116039146\ \(0\)\
\-\ to\\:\\ 0\\.051366267931291114\ \(0\)\
\-\ occur\\:\\ 0\\.05037005681145229\ \(0\)\
\-\ extremity\\:\\ 0\\.04932898876052055\ \(0\)\
\-\ typically\\:\\ 0\\.048079953838325716\ \(0\)\
\-\ was\\:\\ 0\\.04773811621858777\ \(0\)\
\-\ labs\\:\\ 0\\.0474497355145346\ \(0\)\
\-\ 30\\:\\ 0\\.046721851829747245\ \(0\)\
\-\ elevated\\:\\ 0\\.04668979198768567\ \(0\)\
\-\ decreased\\:\\ 0\\.04242342783475989\ \(0\)\
\-\ the\\:\\ 0\\.04099804889807151\ \(0\)\
\-\ carcinoma\\:\\ 0\\.04096696160357009\ \(0\)\
\-\ edema\\:\\ 0\\.04084828119356763\ \(0\)\
\-\ she\\:\\ 0\\.04076980768729431\ \(0\)\
\-\ two\\:\\ 0\\.04067243161648447\ \(0\)\
\-\ with\\:\\ 0\\.04023294585530029\ \(0\)\
\-\ physical\\:\\ 0\\.03713625129841047\ \(0\)\
\-\ consistent\\:\\ 0\\.03713625129841047\ \(0\)\
\-\ lower\\:\\ 0\\.03499790036036792\ \(0\)\
\-\ exam\\:\\ 0\\.03447734418706741\ \(0\)\
\-\ but\\:\\ 0\\.03386786578530538\ \(0\)\
\-\ findings\\:\\ 0\\.033802016970971016\ \(0\)\
\-\ female\\:\\ 0\\.033049050932737786\ \(0\)\
\-\ presents\\:\\ 0\\.03294669392987436\ \(0\)\
\-\ within\\:\\ 0\\.03154387325604213\ \(0\)\
\-\ be\\:\\ 0\\.02778320681578715\ \(0\)\
\-\ or\\:\\ 0\\.023826067160849312\ \(0\)\
\-\ this\\:\\ 0\\.02353401783410604\ \(0\)\
\-\ year\\:\\ 0\\.02110692912277963\ \(0\)\
\-\ old\\:\\ 0\\.020269958302702753\ \(0\)\
\-\ is\\:\\ 0\\.01875614931189336\ \(0\)\
